Abbott Hospital Products Spin-Off Will Free Up $500 Mil. For Rx Spending
Executive Summary
Abbott's planned spin-off of a new hospital products company will free up approximately $500 mil. to invest in R&D and promotional support for Humira
You may also be interested in...
Abbott “Knolls” When To Quit: Large-Scale Mergers Not On Agenda, CEO Says
Abbott's acquisition of Knoll has given the company enough "critical mass" to meet its pharmaceutical growth goals, Abbott CEO Miles White indicated during an investor call Jan. 16
Abbott “Knolls” When To Quit: Large-Scale Mergers Not On Agenda, CEO Says
Abbott's acquisition of Knoll has given the company enough "critical mass" to meet its pharmaceutical growth goals, Abbott CEO Miles White indicated during an investor call Jan. 16
Levitra Is Big News On Wall Street, But Rx Firms Ask Investors To Think Small
GlaxoSmithKline's levitating act in the third quarter shows that co-promotion deals have kept their magic for the company